Acute liver failure has the characteristics of rapid onset, complex condition, and high mortality rate, which greatly limits its prevention and treatment. Animal models are one of the important ways to verify the effectiveness of new technologies and treatment plans. The animal model of acute liver failure established by D-galactosamine combined with low-dose LPS has been widely recognized by scholars at home and abroad, and is commonly used for screening liver protective drugs. This model has high similarity with liver failure caused by viral hepatitis in clinical practice.

Observation indicators

Biochemical detection of AST, ALT, MDA, GSH, SOD content; Inflammatory factors such as TNF - α, IL-1β,、IL-6 ,、IFN-γ,、IL-10 ,； Liver pathological examination, etc.

Partial experimental diagram display